Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | F9 | P00740 | 2/20 | 0.44 |
| ▸ | F7 | P08709 | 2/20 | 0.44 |
| ▸ | COMT | P21964 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 3/20 | 0.43 |
| ▸ | RAB9A | P51151 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | ABL1 | P00519 | 1/20 | 0.42 |
| ▸ | FABP6 | P51161 | 1/20 | 0.42 |
| ▸ | F11 | P03951 | 1/20 | 0.42 |
| ▸ | TYMS | P04818 | 2/20 | 0.41 |
| ▸ | SCD | O00767 | 3/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL335500 | 0.94 | F9 (0.44) | KDRSMN1; SMN2F9F7NPC1 | |
| SCHEMBL336586 | 0.92 | GRIN1 (0.44) | KDRF9F7ABL1FABP6 | |
| SCHEMBL335420 | 0.92 | NPC1 (0.46) | SMN1; SMN2F9F7NPC1RAB9A | |
| SCHEMBL335396 | 0.91 | F7 (0.44) | SMN1; SMN2F9F7NPC1RAB9A | |
| SCHEMBL336367 | 0.90 | MAPT (0.47) | SMN1; SMN2F9F7NPC1RAB9A | |
| SCHEMBL335878 | 0.90 | ABL1 (0.43) | SMN1; SMN2F9F7ABL1FABP6 | |
| SCHEMBL335948 | 0.89 | ABL1 (0.45) | SMN1; SMN2F9F7NPC1RAB9A | |
| SCHEMBL335916 | 0.89 | MTOR (0.46) | KDRSMN1; SMN2F9F7MEN1 | |
| SCHEMBL8219489 | 0.89 | F9 (0.43) | SMN1; SMN2F9F7RAB9AMEN1 | |
| SCHEMBL335390 | 0.89 | ABL1 (0.44) | SMN1; SMN2F9F7NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2069289-B1 | ISOSERINE DERIVATIVES FOR USE AS COAGULATION FACTOR IXa INHIBITORS | SANOFI SA (FR) | 2013-10-02 | — | — | EP | claimed |
| US-8097758-B2 | Isoserine derivatives for use as coagulation factor IXa inhibitors | SANOFI-AVENTIS (FR) | 2012-01-17 | — | — | US | claimed |
| US-20090233949-A1 | ISOSERINE DERIVATIVES FOR USE AS COAGULATION FACTOR IXA INHIBITORS | SANOFI-AVENTIS (FR) | 2009-09-17 | — | — | US | claimed |
| CN-101516834-A | Isoserine derivatives for use as coagulation factor ixa inhibitors | SANOFI AVENTIS (FR) | 2009-08-26 | — | — | CN | claimed |
| EP-2069289-A1 | ISOSERINE DERIVATIVES FOR USE AS COAGULATION FACTOR IXa INHIBITORS | Sanofi-Aventis (FR) | 2009-06-17 | — | — | EP | claimed |
| WO-2008031509-A1 | ISOSERINE DERIVATIVES FOR USE AS COAGULATION FACTOR IXa INHIBITORS | SANOFI-AVENTIS (FR) | 2008-03-20 | — | — | WO | claimed |
| EP-2069289-B1 | ISOSERINE DERIVATIVES FOR USE AS COAGULATION FACTOR IXa INHIBITORS | SANOFI SA (FR) | 2013-10-02 | — | — | EP | disclosed |
| CN-1359423-A | Herbicide resistant plants | HINZENTA CO LTD (GB) | 2002-07-17 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233949-A1 | ISOSERINE DERIVATIVES FOR USE AS COAGULATION FACTOR IXA INHIBITORS | TFPI, F2, F9 | KDR 4305/4885SMN1; SMN2 4382/4885F9 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.